Publicacións en colaboración con investigadores/as de Universidad Complutense de Madrid (13)

2023

  1. The Five “Ws” of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When

    Cancers, Vol. 15, Núm. 17

2022

  1. TRAF3 alterations are frequent in del-3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 903-914

  2. Uso de las redes sociales Twitter e Instagram como herramientas docentes para la enseñanza de la genética clínica en la Universidad de Salamanca

    La necesidad de la transformación social desde la innovación docente y educativa (Aula Magna), pp. 261-279

2021

  1. From biomarkers to models in the changing landscape of chronic lymphocytic leukemia: Evolve or become extinct

    Cancers, Vol. 13, Núm. 8

  2. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment

    Diagnostics, Vol. 11, Núm. 5

2020

  1. Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 548-555.e4

2018

  1. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 3, pp. 633-642

  2. The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers only Prognostic Model and the MD Anderson Cancer Center Prognostic Index

    BioMed Research International, Vol. 2018

2017

  1. Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL

    European Journal of Haematology, Vol. 98, Núm. 2, pp. 142-148

2016

  1. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

    Hematological Oncology, Vol. 34, Núm. 2, pp. 84-92

  2. Pharmacogenetics and pharmacogenomics as tools in cancer therapy

    Drug Metabolism and Personalized Therapy, Vol. 31, Núm. 1, pp. 25-34

2015

  1. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia

    BioMed Research International, Vol. 2014